BioCentury
ARTICLE | Company News

Flamel, GlaxoSmithKline deal

March 30, 2009 7:00 AM UTC

Flamel will receive a $4 million milestone from GlaxoSmithKline under a 2004 deal for Flamel to manufacture the pharma's Coreg CR, a controlled-release formulation of the beta blocker Coreg carvedilo...